Repligen (NASDAQ:RGEN) Shares Up 4.5% Following Earnings Beat

Shares of Repligen Corporation (NASDAQ:RGEN) traded up 4.5% during mid-day trading on Wednesday following a stronger than expected earnings report. The stock traded as high as $185.29 and last traded at $183.7640. Approximately 163,772 shares were traded during mid-day trading, a decline of 84% from the average daily volume of 1,049,196 shares. The stock had previously closed at $175.80.

The biotechnology company reported $0.53 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.46 by $0.07. The company had revenue of $209.31 million during the quarter, compared to analysts’ expectations of $206.71 million. During the same quarter last year, the company earned $0.46 earnings per share. Repligen’s revenue for the quarter was up 10.9% on a year-over-year basis.

Repligen News Roundup

Here are the key news stories impacting Repligen this week:

• Positive Sentiment: Repligen reported third-quarter revenue of $209.3 million, up 10.9% year over year and above the roughly $206.7 million consensus estimate. Adjusted EPS of $0.53 also exceeded expectations of $0.46. Repligen Q3 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Management raised full-year 2026 revenue guidance to $844 million-$852 million, representing approximately 14.5%-15.5% reported growth. The company also completed its BioLife acquisition, expanding its cell-therapy offerings and potentially accelerating long-term growth. Repligen Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
• Positive Sentiment: Some commentary characterized the revenue outlook as a potential catalyst and argued that RGEN could be undervalued if its growth and cash-flow expansion continue. Repligen Could Be 12% Undervalued
• Neutral Sentiment: Valuation remains a key debate. With a very high earnings multiple, one analysis viewed the stock as fairly valued because expected cash-flow growth is already reflected in the share price. Repligen Stock Looks Fairly Valued
• Negative Sentiment: Repligen recorded a $41.2 million impairment charge, causing reported quarterly profit to turn into a loss. Although the charge is noncash, it weakens GAAP results and may prompt investors to focus more heavily on adjusted figures. Repligen Takes $41.2 Million Impairment Charge
• Negative Sentiment: The Filtration segment remained weak, and management said some expected system deliveries moved into 2027. That delay creates near-term uncertainty despite strength in Proteins, Chromatography, and Analytics, likely explaining the market’s negative reaction to otherwise solid results. Repligen Slips as Investors Weigh Filtration Weakness

Analysts Set New Price Targets

Several brokerages have recently issued reports on RGEN. UBS Group reissued a “buy” rating on shares of Repligen in a research report on Tuesday, September 29th. JPMorgan Chase & Co. boosted their target price on Repligen from $165.00 to $175.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. Weiss Ratings raised Repligen from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, October 8th. Zacks Research downgraded shares of Repligen from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 28th. Finally, Canaccord Genuity Group increased their price target on Repligen from $145.00 to $180.00 and gave the stock a “hold” rating in a report on Monday, October 19th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $175.71.

Institutional Trading of Repligen

Several institutional investors and hedge funds have recently made changes to their positions in RGEN. United Capital Financial Advisors LLC purchased a new position in Repligen in the 2nd quarter valued at about $380,756,000. Wasatch Advisors LP grew its holdings in Repligen by 27.9% in the second quarter. Wasatch Advisors LP now owns 1,590,251 shares of the biotechnology company’s stock valued at $216,974,000 after purchasing an additional 346,720 shares during the period. Congress Asset Management Co. grew its holdings in Repligen by 0.9% in the third quarter. Congress Asset Management Co. now owns 1,020,907 shares of the biotechnology company’s stock valued at $196,249,000 after purchasing an additional 8,681 shares during the period. ABS Investment Management LLC acquired a new position in Repligen during the second quarter worth approximately $191,016,000. Finally, Maverick Capital Ltd. acquired a new position in Repligen during the first quarter worth approximately $178,946,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Repligen Stock Up 4.5%

The company has a market cap of $10.37 billion, a PE ratio of 251.19 and a beta of 1.08. The stock’s 50 day simple moving average is $177.50 and its two-hundred day simple moving average is $144.99.

About Repligen

Repligen Corporation (NASDAQ:RGEN) develops and manufactures bioprocessing technologies used in the production of biological medicines. Its products support key stages of biopharmaceutical manufacturing, including upstream processing, downstream purification, filtration, process monitoring and fluid management.

The company’s offerings include chromatography products, filtration systems, single-use technologies, process analytics equipment and critical biological materials such as recombinant proteins.